Cargando…

Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson’s disease treatment

Sustainable and safe delivery of brain-targeted drugs is highly important for successful therapy in Parkinson’s disease (PD). This study was designed to formulate biodegradable poly(ethylene glycol)–poly(lactic-co-glycolic acid) (PEG-PLGA) nanoparticles (NPs), which were surface-modified with lactof...

Descripción completa

Detalles Bibliográficos
Autores principales: Bi, Chenchen, Wang, Aiping, Chu, Yongchao, Liu, Sha, Mu, Hongjie, Liu, Wanhui, Wu, Zimei, Sun, Kaoxiang, Li, Youxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153272/
https://www.ncbi.nlm.nih.gov/pubmed/27994458
http://dx.doi.org/10.2147/IJN.S120939
_version_ 1782474663744503808
author Bi, Chenchen
Wang, Aiping
Chu, Yongchao
Liu, Sha
Mu, Hongjie
Liu, Wanhui
Wu, Zimei
Sun, Kaoxiang
Li, Youxin
author_facet Bi, Chenchen
Wang, Aiping
Chu, Yongchao
Liu, Sha
Mu, Hongjie
Liu, Wanhui
Wu, Zimei
Sun, Kaoxiang
Li, Youxin
author_sort Bi, Chenchen
collection PubMed
description Sustainable and safe delivery of brain-targeted drugs is highly important for successful therapy in Parkinson’s disease (PD). This study was designed to formulate biodegradable poly(ethylene glycol)–poly(lactic-co-glycolic acid) (PEG-PLGA) nanoparticles (NPs), which were surface-modified with lactoferrin (Lf), for efficient intranasal delivery of rotigotine to the brain for the treatment of PD. Rotigotine NPs were prepared by nanoprecipitation, and the effect of various independent process variables on the resulting properties of NPs was investigated by a Box–Behnken experimental design. The physicochemical and pharmaceutical properties of the NPs and Lf-NPs were characterized, and the release kinetics suggested that both NPs and Lf-NPs provided continuous, slow release of rotigotine for 48 h. Neither rotigotine NPs nor Lf-NPs reduced the viability of 16HBE and SH-SY5Y cells; in contrast, free rotigotine was cytotoxic. Qualitative and quantitative cellular uptake studies demonstrated that accumulation of Lf-NPs was greater than that of NPs in 16HBE and SH-SY5Y cells. Following intranasal administration, brain delivery of rotigotine was much more effective with Lf-NPs than with NPs. The brain distribution of rotigotine was heterogeneous, with a higher concentration in the striatum, the primary region affected in PD. This strongly suggested that Lf-NPs enable the targeted delivery of rotigotine for the treatment of PD. Taken together, these results demonstrated that Lf-NPs have potential as a carrier for nose-to-brain delivery of rotigotine for the treatment of PD.
format Online
Article
Text
id pubmed-5153272
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-51532722016-12-19 Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson’s disease treatment Bi, Chenchen Wang, Aiping Chu, Yongchao Liu, Sha Mu, Hongjie Liu, Wanhui Wu, Zimei Sun, Kaoxiang Li, Youxin Int J Nanomedicine Original Research Sustainable and safe delivery of brain-targeted drugs is highly important for successful therapy in Parkinson’s disease (PD). This study was designed to formulate biodegradable poly(ethylene glycol)–poly(lactic-co-glycolic acid) (PEG-PLGA) nanoparticles (NPs), which were surface-modified with lactoferrin (Lf), for efficient intranasal delivery of rotigotine to the brain for the treatment of PD. Rotigotine NPs were prepared by nanoprecipitation, and the effect of various independent process variables on the resulting properties of NPs was investigated by a Box–Behnken experimental design. The physicochemical and pharmaceutical properties of the NPs and Lf-NPs were characterized, and the release kinetics suggested that both NPs and Lf-NPs provided continuous, slow release of rotigotine for 48 h. Neither rotigotine NPs nor Lf-NPs reduced the viability of 16HBE and SH-SY5Y cells; in contrast, free rotigotine was cytotoxic. Qualitative and quantitative cellular uptake studies demonstrated that accumulation of Lf-NPs was greater than that of NPs in 16HBE and SH-SY5Y cells. Following intranasal administration, brain delivery of rotigotine was much more effective with Lf-NPs than with NPs. The brain distribution of rotigotine was heterogeneous, with a higher concentration in the striatum, the primary region affected in PD. This strongly suggested that Lf-NPs enable the targeted delivery of rotigotine for the treatment of PD. Taken together, these results demonstrated that Lf-NPs have potential as a carrier for nose-to-brain delivery of rotigotine for the treatment of PD. Dove Medical Press 2016-12-07 /pmc/articles/PMC5153272/ /pubmed/27994458 http://dx.doi.org/10.2147/IJN.S120939 Text en © 2016 Bi et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Bi, Chenchen
Wang, Aiping
Chu, Yongchao
Liu, Sha
Mu, Hongjie
Liu, Wanhui
Wu, Zimei
Sun, Kaoxiang
Li, Youxin
Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson’s disease treatment
title Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson’s disease treatment
title_full Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson’s disease treatment
title_fullStr Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson’s disease treatment
title_full_unstemmed Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson’s disease treatment
title_short Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson’s disease treatment
title_sort intranasal delivery of rotigotine to the brain with lactoferrin-modified peg-plga nanoparticles for parkinson’s disease treatment
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153272/
https://www.ncbi.nlm.nih.gov/pubmed/27994458
http://dx.doi.org/10.2147/IJN.S120939
work_keys_str_mv AT bichenchen intranasaldeliveryofrotigotinetothebrainwithlactoferrinmodifiedpegplgananoparticlesforparkinsonsdiseasetreatment
AT wangaiping intranasaldeliveryofrotigotinetothebrainwithlactoferrinmodifiedpegplgananoparticlesforparkinsonsdiseasetreatment
AT chuyongchao intranasaldeliveryofrotigotinetothebrainwithlactoferrinmodifiedpegplgananoparticlesforparkinsonsdiseasetreatment
AT liusha intranasaldeliveryofrotigotinetothebrainwithlactoferrinmodifiedpegplgananoparticlesforparkinsonsdiseasetreatment
AT muhongjie intranasaldeliveryofrotigotinetothebrainwithlactoferrinmodifiedpegplgananoparticlesforparkinsonsdiseasetreatment
AT liuwanhui intranasaldeliveryofrotigotinetothebrainwithlactoferrinmodifiedpegplgananoparticlesforparkinsonsdiseasetreatment
AT wuzimei intranasaldeliveryofrotigotinetothebrainwithlactoferrinmodifiedpegplgananoparticlesforparkinsonsdiseasetreatment
AT sunkaoxiang intranasaldeliveryofrotigotinetothebrainwithlactoferrinmodifiedpegplgananoparticlesforparkinsonsdiseasetreatment
AT liyouxin intranasaldeliveryofrotigotinetothebrainwithlactoferrinmodifiedpegplgananoparticlesforparkinsonsdiseasetreatment